ArticleCancer medicine2019
Elevated serum HER-2 predicts poor prognosis in breast cancer and is correlated to ADAM10 expression.
Article in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Soluble isoforms of EGFR family in breast cancer: Advances and clinical relevance (Review).Oncology letters · 2026Review
- Breast cancer immunotherapy: mechanisms of immune evasion, biomarkers, and emerging therapeutic strategies.Molecular cancer · 2026Review
- Exosome crown proteins are promising markers for liquid biopsy of breast cancer.Frontiers in oncology · 2026Review
- Advancing Breast Cancer Treatment: The Role of Immunotherapy and Cancer Vaccines in Overcoming Therapeutic Challenges.Vaccines · 2025Review
- Clinical utility of quantitative ultrasonography parameters combined with serum cancer antigen 15‑3, human epidermal growth factor receptor 2 and soluble E‑cadherin in diagnosing mass‑type breast cancer.Oncology letters · 2025Article
- Investigation ofMicroorganisms · 2024Article
- Secretase promotes AD progression: simultaneously cleave Notch and APP.Frontiers in aging neuroscience · 2024Review
- Prognostic Value of Erythroblastic Leukemia Viral Oncogene Homolog 2 and Neuregulin 4 in Hepatocellular Carcinoma.Cancers · 2023Article
- Resistance to Trastuzumab.Cancers · 2022Review
- Circular RNA circ-ERBB2 promotes HER2-positive breast cancer progression and metastasis via sponging miR-136-5p and miR-198.Journal of translational medicine · 2021Article
- TTK is a potential therapeutic target for cisplatin-resistant ovarian cancer.Journal of ovarian research · 2021Article
- Regulation of ADAM10 by the TspanC8 Family of Tetraspanins and Their Therapeutic Potential.International journal of molecular sciences · 2021Review
- Serum HER2 levels predict treatment efficacy and prognosis in patients with HER2-positive breast cancer undergoing neoadjuvant treatment.Gland surgery · 2021Article
- ADAM10 is involved in the oncogenic process and chemo-resistance of triple-negative breast cancer via regulating Notch1 signaling pathway, CD44 and PrPc.Cancer cell international · 2021Article
- Exosome-mediated lncRNA AFAP1-AS1 promotes trastuzumab resistance through binding with AUF1 and activating ERBB2 translation.Molecular cancer · 2020Article
- Targeting ADAM10 in Cancer and Autoimmunity.Frontiers in immunology · 2020Review
- Elevated serum HER-2 predicts poor prognosis in breast cancer and is correlated to ADAM10 expression.Cancer medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human epidermal growth factor receptor-2 (HER-2) overexpression in breast tumor tissues is associated with a poor prognosis but may benefit from treatment with trastuzumab. The extracellular domain (ECD) of HER-2 can be measured in serum and which has been a new inspection item in clinical laboratory of several hospitals. However, whether serum HER-2 ECD can be a marker of HER-2 status in tumor tissues still confused clinicians. This study is a retrospective observation to explore the correlation between serum HER-2 ECD shedding and tissue HER-2 status in breast cancer patients. Meanwhile, we will further uncover the potential clinical significance of serum HER-2 ECD detection. A total of 545 unselected breast cancer patients from Fudan University Shanghai Cancer Center were enrolled in this study. At primary diagnosis without any treatment, serum HER-2 ECD was measured on ADVIA Centaur assay; meanwhile, tissue HER-2 from core needle biopsy was tested through immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH). We showed that serum HER-2 ECD concentration was related to tissue HER-2 status. Nevertheless, 36.9% of patients with tissue HER-2 overexpression had low levels of HER-2 ECD shedding (<15 ng/mL) in serum. Here, we demonstrated that HER-2 ECD shedding was also associated with protein expression and alpha-secretase activity of a disintegrin and metalloproteinase 10 (ADAM10) using tumor tissues and cell lines. Progression-free survival (PFS) data from breast cancer patients in TNM phase II and III with tissue HER-2 IHC 3+ were analyzed using Kaplan-Meier plotter. The patients with serum HER-2 ECD above 15 ng/mL had lower progression-free survival than those with serum HER-2 ECD <15 ng/mL. Thus, serum HER-2 ECD could be a biomarker to identify the subgroup of poorer outcome among HER-2 overexpression breast cancer patients. Inhibition of ADAM10 activity may have potential therapeutic benefit for this most aggressive tumor subgroup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.